2023
DOI: 10.1016/s1473-3099(22)00318-8
|View full text |Cite|
|
Sign up to set email alerts
|

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
78
0
18

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 87 publications
(97 citation statements)
references
References 28 publications
1
78
0
18
Order By: Relevance
“…In the multicentre Phase II MYR-202 study, 118 tenofovir-treated patients were randomized to different BLV doses (2, 5 or 10 mg/day) or tenofovir monotherapy for 24 weeks followed by 24 weeks of tenofovir alone. 19 Approximately half of patients had baseline compensated cirrhosis. A dose-dependent reduction in HDV-RNA and ALT was noticed.…”
Section: Clinical Development: the Myr Trialsmentioning
confidence: 99%
“…In the multicentre Phase II MYR-202 study, 118 tenofovir-treated patients were randomized to different BLV doses (2, 5 or 10 mg/day) or tenofovir monotherapy for 24 weeks followed by 24 weeks of tenofovir alone. 19 Approximately half of patients had baseline compensated cirrhosis. A dose-dependent reduction in HDV-RNA and ALT was noticed.…”
Section: Clinical Development: the Myr Trialsmentioning
confidence: 99%
“…These studies explore the role of treatment duration, selection of the optimal dose of BLV, and the need to combine BLV with PEGIFN. Based on the published interim date of these studies and some “real-world” studies [ 14 , 17 , 21 , 22 ], there is an impression that the addition of PEGIFN and/or using higher BLV doses result in higher virologic response rates.…”
Section: Guidance On How To Use Blv In Patients With Chronic Hepatitis Dmentioning
confidence: 99%
“…Second, the optimal dose of BLV is uncertain; the market authorization has only been obtained for the 2 mg/d dose, while higher BLV doses may be more effective [ 14 ]. In our study [ 23 ], 20 of 21 patients who received the initial dose of 2 mg/d had some virological response (any log decline) at week 24.…”
Section: Guidance On How To Use Blv In Patients With Chronic Hepatitis Dmentioning
confidence: 99%
See 2 more Smart Citations